רוויקטי  1.1 ג מל ישראל - עברית - Ministry of Health

רוויקטי 1.1 ג מל

medison pharma ltd - glycerol phenylbutyrate - נוזל - glycerol phenylbutyrate 1.1 g / 1 ml - glycerol phenylbutyrate

רוויקטי  1.1 ג מל ישראל - עברית - Ministry of Health

רוויקטי 1.1 ג מל

medison pharma ltd - glycerol phenylbutyrate - נוזל - glycerol phenylbutyrate 1.1 g / 1 ml - glycerol phenylbutyrate

רוויקטי  1.1 ג מל ישראל - עברית - Ministry of Health

רוויקטי 1.1 ג מל

medison pharma ltd - glycerol phenylbutyrate - נוזל - glycerol phenylbutyrate 1.1 g / 1 ml - glycerol phenylbutyrate

ג'ארדיאנס 10 מג ישראל - עברית - Ministry of Health

ג'ארדיאנס 10 מג

boehringer ingelheim israel ltd. - empagliflozin - טבליות מצופות פילם - empagliflozin 10 mg - linagliptin and empagliflozin

ג'ארדיאנס 25 מג ישראל - עברית - Ministry of Health

ג'ארדיאנס 25 מג

boehringer ingelheim israel ltd. - empagliflozin - טבליות מצופות פילם - empagliflozin 25 mg - linagliptin and empagliflozin

אקטוס 15 מג ישראל - עברית - Ministry of Health

אקטוס 15 מג

tzamal bio-pharma ltd - pioglitazone as hydrochloride - טבליה - pioglitazone as hydrochloride 15 mg - pioglitazone - pioglitazone - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapy - in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance as dual oral therapy in combination with- metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination with - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.- pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients wi

אקטוס 30 מג ישראל - עברית - Ministry of Health

אקטוס 30 מג

tzamal bio-pharma ltd - pioglitazone as hydrochloride - טבליה - pioglitazone as hydrochloride 30 mg - pioglitazone - pioglitazone - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapy - in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance as dual oral therapy in combination with- metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination with - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.- pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients wi

אקטוס 45 מג ישראל - עברית - Ministry of Health

אקטוס 45 מג

tzamal bio-pharma ltd - pioglitazone as hydrochloride - טבליה - pioglitazone as hydrochloride 45 mg - pioglitazone - pioglitazone - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapy - in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance as dual oral therapy in combination with- metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination with - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.- pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients wi

ויקטוזה ישראל - עברית - Ministry of Health

ויקטוזה

novo nordisk ltd., israel - liraglutide - תמיסה להזרקה - liraglutide 6.0 mg/ml - liraglutide - liraglutide - for the treatment of adults with type 2 diabetes mellitus to achieve glycemic control : in combination with : - metformin or a sulphonylurea, in patients with insufficient glycemic control despite maximal tolerated dose of monotherapy with mentformin or sulphonylurea. - metformin and sulphonylurea or metformin and a thiazolidinedione in patients with insufficient glycemic control despite dual therapy.

סטאפידרם קרם ישראל - עברית - Ministry of Health

סטאפידרם קרם

trima israel pharmaceutical products maabarot ltd - fusidic acid - קרם - fusidic acid 2 % - fusidic acid - fusidic acid - local treatment of skin infections due to sensitive strains of staphylococcus aureus